Golden Ally Lifetech Group, Inc.
AQPW · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 2.01 | -0.09 | 0.00 |
| FCF Yield | -26.55% | -1.53% | -4.42% | -2.87% |
| EV / EBITDA | -3.72 | 41.50 | -10.52 | -33.13 |
| Quality | ||||
| ROIC | -344.65% | -2.35% | -272.77% | 38.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.91 | 0.48 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -3,724.14% | 5.94% | -54.35% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | -16.76 | 0.28 | 0.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -214.96 | 0.00 | 0.00 | 0.00 |